REPL
Déjà vu, but make it regulatory
Replimune just took another hit from the FDA over RP1, its melanoma therapy. If you’re keeping score at home, this is not the kind of sequel shareholders wanted.
Why investors care
A second CRL means the agency still isn’t convinced the package is ready for prime time. That usually translates into more delay, more uncertainty, and a bigger cloud hanging over the pipeline — exactly the stuff biotech stocks hate most.
The messy part
When a lead asset gets stuck in the FDA’s revolving door, the market starts asking the annoying questions:
- How long until a real path forward emerges?
- Does the company need to rework the data or the filing?
- And how much value was riding on RP1 in the first place?
Big picture
Biotech is a land of binary outcomes, and this one keeps landing on the wrong side of the coin flip. Until Replimune shows a clean regulatory path, the stock may keep trading like a therapy with more paperwork than potential.